a proto-oncogenic transcription factor homologous to the v-ets erythroblastosis virus oncogene. The DNA binding activity of Ets1 is controlled by kinases and transcription factors. It contributes to the regulation of cellular differentiation in hematopoietic cells. Ets1 promotes invasive behavior in endothelial cells, vascular smooth muscle cells and epithelial cancer cells. Regulates the expression of MMP1, MMP3, MMP9 and uPA as well as of VEGF and VEGFR gene expression. Two alternatively spliced isoforms have been described. Note: This description may include information from UniProtKB.
Protein type: Oncoprotein; Motility/polarity/chemotaxis; DNA-binding; Transcription factor
Molecular Function: DNA binding; histone acetyltransferase binding; identical protein binding; protein binding; sequence-specific DNA binding; transcription factor activity; transcription factor binding
Biological Process: angiogenesis involved in wound healing; cell differentiation; cell motility involved in cell locomotion; female pregnancy; hypothalamus development; immune response; negative regulation of cell cycle; negative regulation of cell proliferation; negative regulation of inflammatory response; pituitary gland development; PML body organization and biogenesis; positive regulation of angiogenesis; positive regulation of cell motility; positive regulation of cell proliferation; positive regulation of erythrocyte differentiation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; regulation of angiogenesis; regulation of apoptosis; response to antibiotic; response to estradiol stimulus; response to hypoxia; response to mechanical stimulus; transcription from RNA polymerase II promoter; transcription, DNA-dependent
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.